Abstract 19342: The Impact of PCSK9 Inhibitors on Lipid Levels and Outcomes in Patients With Primary Hypercholesterolemia: A Network Meta-analysis

Introduction: We performed a network meta-analysis of randomized controlled trials (RCTs) in patients with primary hypercholesterolemia to compare the impact of PCSK9 inhibitors with placebo and ezetimibe on lipid levels and outcomes. Hypothesis: PCSK9 inhibitors will significantly lower LDL-C greater than ezetimibe and improve outcomes. Methods: MEDLINE/PubMed, Cochrane CENTRAL, and ClinicalTrials.gov were searched for RCTs assessing PCSK9...